These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 36777069)
21. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease. Kim JY; Bhat S Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881 [TBL] [Abstract][Full Text] [Related]
22. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
24. Biosimilars in the therapy of inflammatory bowel diseases. Hlavaty T; Letkovsky J Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561 [TBL] [Abstract][Full Text] [Related]
25. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Scott FI; Lichtenstein GR Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747 [TBL] [Abstract][Full Text] [Related]
26. Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Fisher A; Kim JD; Dormuth CR Gastroenterol Res Pract; 2023; 2023():2794220. PubMed ID: 36911254 [TBL] [Abstract][Full Text] [Related]
27. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related]
28. The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics. Limdi JK; Farraye FA Crohns Colitis 360; 2021 Jul; 3(3):otab015. PubMed ID: 36776664 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related]
30. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174 [TBL] [Abstract][Full Text] [Related]
31. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. Mansell K; Bhimji H; Eurich D; Mansell H BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624 [TBL] [Abstract][Full Text] [Related]
32. Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease. Yossef L; Wright M; Benedict J; Morris GA; McNicol M; Boyle B; Dotson JL; Michel HK; Maltz RM J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):59-63. PubMed ID: 35442227 [TBL] [Abstract][Full Text] [Related]
33. Biosimilars for the treatment of psoriasis. Puig L; López-Ferrer A Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786 [No Abstract] [Full Text] [Related]
34. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332 [TBL] [Abstract][Full Text] [Related]
35. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability. Lasala R; Abrate P; Zovi A; Santoleri F Ther Innov Regul Sci; 2023 Mar; 57(2):352-364. PubMed ID: 36322326 [TBL] [Abstract][Full Text] [Related]
36. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study. Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624 [TBL] [Abstract][Full Text] [Related]
37. A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease. Kashima S; Sawada K; Moriichi K; Fujiya M Ther Adv Drug Saf; 2022; 13():20420986221100118. PubMed ID: 35646305 [TBL] [Abstract][Full Text] [Related]
38. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars. Zeng Z; Lin H; Jiang M; Yuan J; Li X; Jia Y; Yang L; Zhang H Front Pharmacol; 2024; 15():1424606. PubMed ID: 39114362 [TBL] [Abstract][Full Text] [Related]
39. "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars. Varma M; Almarsdóttir AB; Druedahl LC Basic Clin Pharmacol Toxicol; 2022 May; 130(5):581-591. PubMed ID: 35261174 [TBL] [Abstract][Full Text] [Related]